All News
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus
Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting.
https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Links:
Dr. John Cush RheumNow ( View Tweet)
Excellent talk on SLE, APS abs pregancy
⭐️pregnancy counseling is important
⭐️aspirin 81mg in all pregnant SLE pts
⭐️do not discontinue HCQ
⭐️stable LN - can switch MMF to AZA
Abs#6888
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Close call between LLDAS and DORIS Remission as a treat-to-target in #SLE. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/r3OnSrmQkH
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Results are out. The majority would use #anifrolumab to treat refractory skin and joints disease #SLE. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/wguBCkhZ7B
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
6. Rheum disease activity was stable with COVID vaccination.
(RA, PsA, axSpA, SLE - total n = 597)
7/
LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew drdavidliew ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
We need to revisit #SLEDAI #lupus arthritis. Drs Mahmoud & Vital reported only 48% without swelling had MSK-US synovitis; 90% with swelling. They proposed new TERM: Inflammatory joint pain with =>2 SJC. Need to get this right as it impacts SRI-4 #EULAR2021 #POS0746 @RheumNow https://t.co/JPqOMLQ2ES
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE Molecular Phenotype for Personalized Medicine: Drs. Yusof and Garantziotis #EULAR2021
https://t.co/HJzyXBJ0fZ https://t.co/06jvGcczmi
Links:
Dr. John Cush RheumNow ( View Tweet)
Would it help to record #SLE BILAG-2004 index in your busy clinic if this was made easy? Dr Carter reformatted EASY-BILAG with colour-coding and in-built glossary. Most assessment can be done in 1 page!This tool boosts accuracy, speed & usability #EULAR2021 #POS0748 @RheumNow https://t.co/v27rrK0ob3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Would you use #Telemedicine (TM) to follow-up #SLE patients post #COVID? Dr So showed in an RCT (N=122),patient satisfaction and time-to-review were better in TM vs Face-to-Face. Although none had COVID, >pts in TM were hospitalised and trend to⬆️FU #EULAR2021 #POS1164 @RheumNow https://t.co/p7aWv4AVm7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 POS0105: Predictors of flare in SLE low disease activity state:
⭐️Ongoing glucocorticoid treatment
⭐️Ongoing immunosuppressant treatment
⭐️Anti-RNP antibody
@RheumNow
Eric Dein ejdein1 ( View Tweet)
How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/z8c8moIQCa
#EULAR2021
Links:
Dr. John Cush RheumNow ( View Tweet)
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg
Links:
Dr. John Cush RheumNow ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021. OP0293: Best disease activity measure for SLE flares?
⭐️c-SFI and SLE-DAS had best performance
⭐️SLE-DAS: easy to use for daily practice
@RheumNow https://t.co/9LJfbYxqOs
Eric Dein ejdein1 ( View Tweet)
BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k
Andy Vermaut AndyVermaut ( View Tweet)
